Searle Pakistan Limited

Searle Pakistan Limited is a pharmaceutical company based in Karachi, Pakistan, dedicated to developing, manufacturing, and marketing a diverse array of healthcare products across multiple therapeutic areas. Searle Pakistan Limited operates in the pharmaceutical sector, focusing on the production of medications. The company's headquarters is located in Karachi, Pakistan. In July 2024, a consortium led by Ijara Capital Partners acquired approximately 90.

61% majority stake in Searle Pakistan Limited from The SEARLE Company Ltd. The company has successfully executed one deal, as indicated by its most recent deal on July 31, 2024. Searle Pakistan Limited specializes in the development, manufacturing, and marketing of a comprehensive range of pharmaceutical products addressing various health needs in therapeutic areas such as cardiovascular health, endocrinology, infectious diseases, and more. Their portfolio includes treatments for both acute and chronic conditions, providing healthcare providers and consumers with effective solutions in regions like South Asia, the Middle East, and parts of Africa.

Searle Pakistan Limited's revenue model is based on direct sales to healthcare institutions, pharmacies, and wholesalers. The company engages in B2B transactions, supplying medications to hospitals and clinics, along with retail partnerships that enhance product availability to consumers. Their offerings include trademarked pharmaceuticals, strategically marketed to cater to healthcare professionals and patients. Looking ahead, Searle Pakistan Limited plans to expand its product offerings with new medications targeting various health conditions.

The company is also focusing on penetrating new geographic markets, particularly in the Middle East and Africa, by the end of 2025. The recent acquisition by Ijara Capital Partners will support these initiatives, leveraging new resources and strategic direction following the acquisition completed on July 31, 2024.